Analyst: This Pharma Stock Could Double After FDA Nod

Evolus stock has already surged 20% out of the gate today

Feb 4, 2019 at 10:08 AM
facebook X logo linkedin


The shares of pharmaceutical concern Evolus Inc (NASDAQ:EOLS) are soaring this morning, after the Food and Drug Administration (FDA) late Friday approved the company's Jeuveau to treat frown lines. The regulatory body back in May declined to approve the Botox rival, but accepted a resubmitted marketing application in August. Out of the gate today, EOLS stock is up 20% to trade at $22, extending Friday's late-session rally.

Cantor Fitzgerald weighed in on EOLS, saying the FDA approval "underscores our positive investment thesis on the stock," which was named one of the brokerage firm's top ideas for 2019. Further, Cantor thinks Wall Street "may be underestimating how quick the uptake of Jeuveau could be," and reiterated an "overweight" rating and $35 price target -- nearly double the equity's close of $18.33 on Friday.

Since touching a near-term bottom of $10.22 on Dec. 24, Evolus stock has more than doubled on the charts, and on Friday topped its 200-day moving average for the first time ever. The security could now face off against the $24 level, which is double EOLS' initial public offering (IPO) price almost one year ago.

A short squeeze could help propel EOLS even higher, though. Short interest on the biotech surged 59% in the past two reporting periods, and now represents 18.4% of the equity's total available float. At the stock's average pace of trading, it would take more than a week to buy back these bearish bets.

 

 

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI